Teva Pharms Usa Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS USA INC, and what generic and branded alternatives to TEVA PHARMS USA INC drugs are available?
TEVA PHARMS USA INC has twenty-eight approved drugs.
There are fourteen tentative approvals on TEVA PHARMS USA INC drugs.
Drugs and US Patents for Teva Pharms Usa Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | CAPSULE;ORAL | 211369-005 | May 2, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Teva Pharms Usa Inc | BREXPIPRAZOLE | brexpiprazole | TABLET;ORAL | 213692-004 | Aug 11, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Teva Pharms Usa Inc | BREXPIPRAZOLE | brexpiprazole | TABLET;ORAL | 213692-003 | Aug 11, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Teva Pharms Usa Inc | LAPATINIB DITOSYLATE | lapatinib ditosylate | TABLET;ORAL | 217968-001 | Aug 16, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS USA INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Similar Applicant Names
Here is a list of applicants with similar names.